Sorafenib is a RAF kinase inhibitor which suppresses ERK phosphorylation. Studies indicate that sorafenib induces c-Raf phosphorylation at both Ser-43 and Ser-259. When combined with vitamin K1, phosphorylation is increased at these serine residues. Sorafenib also induces the phosphorylation of PKA. In addition, sorafenib induces c-Met phosphorylation at Tyr-1349, which consequently induces PI3K-Akt phosphorylation. Studies determined that sorafenib inhibits other kinases such as Flk-1 (VEGFR2), PDGFR (platelet-derived growth factor receptor), Flt-3/Flk-2 (FLT3), Ret, and c-Kit. Sorafenib is an inhibitor of Raf-1, Raf-B, PDGFR-βand Flt-4. Its ability to affect the Raf/Mek/Erk pathway makes it useful in cancer research studies.
1. Richly, H., et al. 2003. Int J Clin Pharmacol Ther. 41: 620-621. PMID: 14692720
2. Khire, U.R., et al. 2004. Bioorg. Med. Chem. Lett. 14: 783-786. PMID: 14741289
3. Wilhelm, S.M., et al. 2004. Cancer Res. 64: 7099-7109. PMID: 15466206
4. Liu, L., et al. 2006. Cancer Res. 66: 11851-11858. PMID: 17178882
5. Rini, B.I. 2006. Expert Opin Pharmacother. 7: 453-461. PMID: 16503817
6. Carr, B.I., et al. 2011. Cancer Biol Ther. [Epub ahead of print]. PMID: 21734462
See how others have used Sorafenib. Click on the entry to view the PubMed entry .
PMID: # 26929621
Petrushev, B. et al. 2016. Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine. 11: 641-60.
PMID: # 26100943
Mani, J. et al. 2016. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737. World J Urol. 34: 197-205.
PMID: # 26808072
Suarasan, S. et al. 2016. Gelatin-coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment. Chem Biol Drug Des. 87: 927-35.
PMID: # 26625890
Simon, T. et al. 2015. Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Res Lett. 10: 466.
Sprinzl, MF. et al. 2015. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J. Hepatol.. 62: 863-70.
PMID: # 26158762
Wei, X. et al. 2015. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Oncotarget. 6: 18389-405.
PMID: # 26301220
Pallegar, NK. et al. 2015. Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K. Front Cell Dev Biol. 3: 47.
PMID: # 23785399
Kwon, JH. et al. 2013. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS ONE. 8: e64260.
PMID: # 23424039
Sprinzl, MF. et al. 2013. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology (Baltimore, Md.). 57: 2358-68.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2017 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.